Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon-alpha and Imatinib Mesylate in Chronic Phase CML
NCT00045422Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Apr 2002
- Primary completion
- Oct 2003
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of interferon alfa in chronic myelogenous leukemia (CML), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Hematologic Response Rate, Cytogenetic Response Rate and 2 more. Started Apr 2002; status: completed.
02
Drugs
interferon alfa
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NCT00045422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00045422.